A Real-World Assessment of Hepatic Dysfunction Among Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Receiving First-Line (1L) Tyrosine Kinase Inhibitors (TKIs) in the United States

被引：0
|
作者：
Kolibaba, Kathryn
Zhou, Jie
Keating, Scott Justin
Clark, Jamyia
Brokars, John
Kee, Arianna
Copher, Ronda
Stwalley, Brian
Jabbour, Elias
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Asciminib After One Prior Tyrosine Kinase Inhibitor (TKI) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Real-World Chart Review Study in the United States (US)
    Atallah, Ehab L.
    Sadek, Islam
    Wei, David
    Latremouille-Viau, Dominick
    Rossi, Carmine
    Damon, Andrea
    Yang, Daisy
    Bellefleur, Remi
    Guerin, Annie
    Jadhav, Kejal
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S365 - S365
  • [22] Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison
    Levy, Moshe Yair
    McGarry, Lisa J.
    Huang, Hui
    Lustgarten, Stephanie
    Nieset, Christopher
    Haluska, Frank G.
    BLOOD, 2014, 124 (21)
  • [23] Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors
    Dahlen, Torsten
    Kockerols, Camille C. B.
    Ferreira, Germano
    Westerweel, Peter E.
    Mayer, Jiri
    Allepuz, Alex
    Wormser, David
    Yau, Lillian
    Zackova, Daniela
    BLOOD, 2022, 140 : 3889 - 3890
  • [24] Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax plus Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
    Ravelo, Arliene
    Patel, Achal
    To, Tu My
    Li, Sophia S.
    Huntington, Scott
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S345 - S345
  • [25] Association Between Treatment Adherence and Response Among Patients With Chronic Myeloid Leukemia (CML) Receiving First-Line TKIs In The Community Setting
    Di Bella, Nicholas J.
    Bhowmik, Debajyoti
    Bhor, Menaka
    Yap, Mark
    Middlebrook, Brooke
    Rembert, Debra
    Dhanda, Rahul
    Cain, Zachary
    Okoro, Tony
    Bolinder, Bjorn
    Jabbour, Elias J.
    BLOOD, 2013, 122 (21)
  • [26] Survival Outcomes in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Receiving Third- or Subsequent Line (3L) Treatment
    Stellato, Daniel R.
    McGarry, Lisa
    Huang, Hui
    Hastings, Shaina
    Delea, Thomas E.
    Lipton, Jeffrey H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S311 - S312
  • [27] Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
    Abdelall, Waleed
    Kantarjian, Hagop M.
    Devendra, K. C.
    Akosile, Mary
    Borthakur, Gautam
    Verstovsek, Srdan
    Daver, Naval
    Pemmaraju, Naveen
    Naqvi, Kiran
    Garcia-Manero, Guillermo
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Ravandi, Farhad
    Konopleva, Marina
    DiNardo, Courtney D.
    Jabbour, Elias J.
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [28] Comparative Efficacy Among 3rd Line Post-Imatinib Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients after Failure of Dasatinib or Nilotinib Tyrosine Kinase Inhibitors
    Lipton, Jeffrey H.
    Shah, Dhvani
    Tongbram, Vanita
    Sidhu, Manpreet K.
    Huang, Hui
    McGarry, Lisa J.
    Lustgarten, Stephanie
    Hawkins, Neil
    BLOOD, 2014, 124 (21)
  • [29] COMPARISON OF PACE CLINICAL TRIAL VS REAL-WORLD PONATINIB PRESCRIBING AND DURATION OF THERAPY IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS
    Mauro, M.
    McGarry, L. J.
    Yang, M.
    Lustgarten, S.
    Huang, H.
    HAEMATOLOGICA, 2016, 101 : 458 - 458
  • [30] High Prevalence of Platelet Dysfunction Among Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors
    Warit, Wangsuekul
    Norasetthada, Lalita
    Tantiworawit, Adisak
    Rattarittamrong, Ekarat
    Chaiadisaksopha, Chatree
    Hantrakool, Sasinee
    Ornkamon, Wongtagan
    Nawarawong, Weerasak
    BLOOD, 2014, 124 (21)
12345